NRx Pharmaceuticals (NASDAQ:NRXP) Earns “Buy” Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $31.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th.

NRx Pharmaceuticals Trading Down 2.9 %

Shares of NRx Pharmaceuticals stock opened at $2.01 on Monday. The stock’s fifty day moving average price is $2.70 and its 200-day moving average price is $2.04. The firm has a market cap of $34.00 million, a P/E ratio of -0.94 and a beta of 1.22. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently bought and sold shares of NRXP. Sassicaia Capital Advisers LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at $33,000. Townsquare Capital LLC acquired a new position in NRx Pharmaceuticals during the 3rd quarter valued at about $25,000. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals in the fourth quarter valued at about $56,000. Millennium Management LLC acquired a new stake in NRx Pharmaceuticals in the fourth quarter worth about $61,000. Finally, Anson Funds Management LP grew its stake in shares of NRx Pharmaceuticals by 30.3% during the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after acquiring an additional 43,135 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.